Just as the summer was creeping in, we hosted our most popular CMN webinar to date. The topic was CRISPR Off-Targets with speakers from academia and a...

This week’s update looks at a Phase 1/2 study for ALLO-501A, a TALEN-edited CAR T-cell therapy for large B-cell lymphoma.

Researchers at University of Freiburg in Germany have developed the first assay to identify and quantify unintended chromosomal rearrangements at on-...

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

Researchers can manipulate genomes at the single-base level, but they still struggle to predict and detect the editing outcomes precisely. Eric Paul...

Update on Allogene Therapeutics off-the-shelf CAR-T cancer therapies. This week’s gene-editing update looks at an investigational new drug (IND)...

We have added 6 new cancer trials to our overview of current clinical trials involving gene editing.

Professor Waseem Qasim, of University College London and Great Ormond Street Institute of Child Health, helps run early-phase clinical trials using...